Literature DB >> 17329332

Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution.

Xiao-Hong Wang1, Dale M Netski, Jacquie Astemborski, Shruti H Mehta, Michael S Torbenson, David L Thomas, Stuart C Ray.   

Abstract

Hepatic fibrosis is the primary mediator of disease due to chronic infection with hepatitis C virus (HCV). HCV exists as a quasispecies in each infected individual, and longitudinal viral sequence changes may reveal viral dynamics and the selection pressures applied by the host immune system. Thus, we hypothesized that patterns of sequence change might reveal the immunopathogenesis of fibrosis progression. We tested this hypothesis by studying individuals enrolled in a prospective study of chronic HCV-related hepatic fibrosis with little or no fibrosis at first biopsy (stage 0 or 1) and a second planned liver biopsy sample obtained 4 years later. Serum was obtained from five individuals with fast progression (FP; defined as a >2-stage change between visits) and 10 carefully matched individuals with slow progression (SP; defined as a <2-stage change between visits). We sequenced multiple cloned hemigenomic cDNAs from each person spanning six genes (core through NS3). Phylogenetic analysis revealed temporal shifts in phylogenetic clustering over time, suggesting frequent quasispecies replacement rather than simple diversification. In addition, mixed infections were detected in three subjects, with coexistence in two subjects (one FP, one SP) of subtypes 1a and 1b throughout the 4-year biopsy interval. Subjects with FP had a higher rate of evolution than subjects with SP, with a preponderance of synonymous changes, suggesting purifying selection, except in hypervariable region 1, where positive selection pressure is frequently detected. Thus, in a small but carefully matched cohort we found evidence for rapid neutral evolution of HCV in persons with rapid progression of hepatic fibrosis, suggesting higher turnover of infected cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329332      PMCID: PMC1900109          DOI: 10.1128/JVI.02276-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

2.  HIV quasispecies and resampling.

Authors:  S L Liu; A G Rodrigo; R Shankarappa; G H Learn; L Hsu; O Davidov; L P Zhao; J I Mullins
Journal:  Science       Date:  1996-07-26       Impact factor: 47.728

3.  Recombinant DNA sequences generated by PCR amplification.

Authors:  R D Bradley; D M Hillis
Journal:  Mol Biol Evol       Date:  1997-05       Impact factor: 16.240

4.  Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies.

Authors:  N Yuki; N Hayashi; T Moribe; Y Matsushita; T Tabata; T Inoue; Y Kanazawa; K Ohkawa; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1997-02       Impact factor: 17.425

5.  Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment.

Authors:  K Koizumi; N Enomoto; M Kurosaki; T Murakami; N Izumi; F Marumo; C Sato
Journal:  Hepatology       Date:  1995-07       Impact factor: 17.425

6.  Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C.

Authors:  R P González-Peralta; K Qian; J Y She; G L Davis; T Ohno; M Mizokami; J Y Lau
Journal:  J Med Virol       Date:  1996-07       Impact factor: 2.327

7.  Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice.

Authors:  L G Guidotti; K Ando; M V Hobbs; T Ishikawa; L Runkel; R D Schreiber; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

8.  Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney.

Authors:  A Widell; S Månsson; N H Persson; H Thysell; S Hermodsson; I Blohme
Journal:  Transplantation       Date:  1995-10-15       Impact factor: 4.939

9.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

10.  Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease.

Authors:  M Naito; N Hayashi; T Moribe; H Hagiwara; E Mita; Y Kanazawa; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

View more
  13 in total

1.  Unexpected maintenance of hepatitis C viral diversity following liver transplantation.

Authors:  Rebecca R Gray; Samantha L Strickland; Nazle M Veras; Maureen M Goodenow; Oliver G Pybus; Stanley M Lemon; Michael W Fried; David R Nelson; Marco Salemi
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

2.  Combined effect of pro- and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients.

Authors:  Nadia Bouzgarrou; Elham Hassen; Olfa Bahri; Sallouha Gabbouj; Nabil Ben Mami; Henda Triki; Lotfi Chouchane
Journal:  Hepatol Int       Date:  2011-02-08       Impact factor: 6.047

3.  Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis.

Authors:  Patrizia Farci; Kurt Wollenberg; Giacomo Diaz; Ronald E Engle; Maria Eliana Lai; Paul Klenerman; Robert H Purcell; Oliver G Pybus; Harvey J Alter
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-24       Impact factor: 11.205

4.  Network Analysis of the Chronic Hepatitis C Virome Defines Hypervariable Region 1 Evolutionary Phenotypes in the Context of Humoral Immune Responses.

Authors:  Brendan A Palmer; Daniel Schmidt-Martin; Zoya Dimitrova; Pavel Skums; Orla Crosbie; Elizabeth Kenny-Walsh; Liam J Fanning
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

5.  Constraints on viral evolution during chronic hepatitis C virus infection arising from a common-source exposure.

Authors:  Justin R Bailey; Sarah Laskey; Lisa N Wasilewski; Supriya Munshaw; Liam J Fanning; Elizabeth Kenny-Walsh; Stuart C Ray
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

6.  Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection.

Authors:  Lin Liu; Brian E Fisher; Kimberly A Dowd; Jacquie Astemborski; Andrea L Cox; Stuart C Ray
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

7.  Hepacivirus A Infection in Horses Defines Distinct Envelope Hypervariable Regions and Elucidates Potential Roles of Viral Strain and Adaptive Immune Status in Determining Envelope Diversity and Infection Outcome.

Authors:  Joshua D Ramsay; Ryan Evanoff; Robert H Mealey
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

8.  Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution.

Authors:  Lin Liu; Brian E Fisher; David L Thomas; Andrea L Cox; Stuart C Ray
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

9.  Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.

Authors:  Hui Li; Brian J McMahon; Susan McArdle; Dana Bruden; Daniel G Sullivan; Dave Shelton; Heike Deubner; David R Gretch
Journal:  Virology       Date:  2008-03-17       Impact factor: 3.616

10.  A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies.

Authors:  Lisa N Wasilewski; Ramy El-Diwany; Supriya Munshaw; Anna E Snider; Jillian K Brady; William O Osburn; Stuart C Ray; Justin R Bailey
Journal:  J Virol       Date:  2016-01-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.